Multi-phaseted problems of TDP-43 in selective neuronal vulnerability in ALS
Kazuhide Asakawa1,2,3, Hiroshi Handa4, Koichi Kawakami5,6
1Department of Chemical Biology, Tokyo Medical University, Shinjuku-ku, Tokyo, 160-8402, Japan. kasakawa@nig.ac.jp.
Cellular and Molecular Life Sciences : CMLS
|March 12, 2021
Summary
Transactive response DNA-binding protein 43 (TDP-43) aggregation in motor neurons is a hallmark of ALS. Understanding wild-type TDP-43 pathology is crucial for developing effective ALS treatments.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- TDP-43, encoded by TARDBP, is vital for RNA metabolism.
- Cytoplasmic aggregation of TDP-43 is a key feature of motor neuron degeneration in ALS.
- Most ALS cases involve wild-type TDP-43, posing a challenge for understanding its pathology.
Purpose of the Study:
- To review current literature on TDP-43 function and regulation in RNP granules.
- To discuss mechanisms linking TDP-43 to motor neuron vulnerability in ALS.
- To explore upstream factors influencing pathological TDP-43 transition.
Main Methods:
- Review of cellular and animal models studying TDP-43 dynamics.
- Analysis of in vivo motor neuron studies, despite anatomical challenges.
- Synthesis of existing literature on TDP-43 and ALS pathogenesis.
Main Results:
- Studies reveal insights into TDP-43's role in RNA metabolism and RNP granule formation.
- Evidence suggests links between TDP-43 dynamics and motor neuron vulnerability.
- Mechanistic insights into pathological TDP-43 transitions are emerging.
Conclusions:
- TDP-43 aggregation is central to motor neuron degeneration in ALS.
- Further research into wild-type TDP-43 pathology is essential for ALS therapeutic development.
- Understanding TDP-43's role in RNP granules may unlock new treatment strategies.
Related Concept Videos
Alzheimer's Disease: Overview
1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K
Alzheimer's Disease: Treatment
555
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
555
Parkinson's Disease: Overview
1.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K


